|Bid||0.5800 x 0|
|Ask||0.6200 x 0|
|Day's Range||0.5800 - 0.6300|
|52 Week Range||0.5000 - 5.9500|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Sep 01, 2020 - Sep 11, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||4.92|
TORONTO and RIONEGRO, Colombia , July 8, 2020 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (PCLO.V) (PCLOF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S., announced today that the Colombian government granted the Company authorization for the 2020 commercial cultivation, production and export of high-THC medicinal cannabis extracts, in fulfilment of existing sales agreements. The commercial quotas obtained from the ministries of Justice and Health, enable the Company to immediately begin cultivation and processing of 10 tonnes of THC-dominant dry flower.
TORONTO , July 3, 2020 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO) (PCLOF) is pleased to announce that it has closed its previously announced "bought deal" offering (the "Offering") of common shares conducted by a syndicate of underwriters, co-led by Cormark Securities Inc. and Stifel GMP (collectively, the "Underwriters"). The Company issued 6,388,940 common shares at a price of $0.72 per common share (the "Offering Price") for aggregate gross proceeds of $4,600,036.80 , including proceeds from the exercise in full of the Underwriters' over-allotment option to purchase 833,340 additional common shares.
TORONTO , June 29, 2020 /CNW/ - PharmaCielo Ltd. (the "Company" or "PharmaCielo") (PCLO.V) (PCLOF) is pleased to announce that it has filed a (final) short form prospectus with the securities regulatory authorities in British Columbia , Alberta , Ontario and Quebec in connection with its previously announced $4 million "bought deal" offering of common shares (the "Offering"), co-led by Cormark Securities Inc. and Stifel GMP. The Offering is expected to close on or about July 3, 2020 and is subject to regulatory approval including that of the TSX Venture Exchange. The net proceeds of the Offering will be used for non-operational payroll expenses of PharmaCielo Colombia S.A.S. ("PharmaCielo Colombia"), non-operational payroll taxes of PharmaCielo Colombia, purchase of ethanol to be used for extraction purposes and other working capital and general corporate purposes.